|
Viridian Therapeutics Inc (NASDAQ: VRDN) |
|
Viridian Therapeutics Inc
VRDN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Viridian Therapeutics Inc 's sales fell
by 0 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1880
Medical Laboratories industry recorded
growth of revenues by 6.35 %
Viridian Therapeutics Inc net loss increased from $-67 millions, to $-80 millions in IV. Quarter 2024,
• More on VRDN's Growth
|
|
Viridian Therapeutics Inc realized a net loss in trailing twelve months.
Viridian Therapeutics Inc realized cash reduction of $ -0.04 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 3930.7.
Medical Laboratories industry's Price to Sales ratio is at 2.17.
• More on VRDN's Valuation
|
|
|
|
|
Viridian Therapeutics Inc realized net loss in trailing twelve months.
Viridian Therapeutics Inc realized cash outflow of $ -0.04per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 3930.7.
Medical Laboratories industry's Price to Sales ratio is at 2.17.
Viridian Therapeutics Inc Price to Book Ratio is at 1.77 lower than Industry Avg. of 147.07. and higher than S&P 500 Avg. of 0.01
• More on VRDN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com